Johnson & Johnson Innovative Medicine
Manufacturing · New Jersey, United States · 17,195 Employees
View Company Info for Free
About
Headquarters
1000 Rte 202, Raritan, New Jersey, 08869, Unite...Website
innovativemedicine.jnj.comRevenue
$5.8 BillionIndustry
Most Recent Scoops
Who is Johnson & Johnson Innovative Medicine
Johnson & Johnson Innovative Medicine Org Chart
Is Johnson & Johnson Innovative Medicine your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Johnson & Johnson Innovative Medicine is spiking on competitors!
Earning: See what the market has to say on Johnson & Johnson Innovative Medicine recently announced quarterly report
Check if Johnson & Johnson Innovative Medicine has recently received funding, and reach out quickly before it becomes old news!
Johnson & Johnson Innovative Medicine, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Click to see if Johnson & Johnson Innovative Medicine had a recent Job posting/layoffs
Product Launch: Get notified when Johnson & Johnson Innovative Medicine launches new products
Congratulate Masked Content for being promoted to Masked Content at Johnson & Johnson Innovative Medicine
Funding: Get notified immidiatlly once Johnson & Johnson Innovative Medicine has new funding data
Recommended Actions
Find VP level buyers at Johnson & Johnson Innovative Medicine
Find 2 more new buyers
Johnson & Johnson Innovative Medicine Employee Growth Rate
Percentage of growth
1st year Mask
2nd year Mask
Most Recent Scoops
Johnson & Johnson Innovative Medicine News & Media
ORIC Pharmaceuticals Announces Clinical Supply Agreement to Evaluate ORIC-114 in Combination with Amivantamab for the First-Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations
Phase 1b combination trial of ORIC-114 and subcutaneous amivantamab in patients with 1L NSCLC with EGFR exon 20 insertion mutations expected to initiate in Q1 2025, with initial data in mid-2026 Phase 1b combination trial of ORIC-114 and subcutaneous amivantamab in patients with 1L NSCLC with EGFR exon 20 insertion mutations expected to initiate in Q1 2025, with initial data in mid-2026The New York Stem Cell Foundation Research Institute Enters Agreement to Accelerate Precision Drug Discovery for Neurodegenerative Disease
Partnership Will Harness NYSCF's Automated Cell Culture Systems and Artificial Intelligence Capabilities to Study Disease at an Unprecedented Cellular Level NEW YORK, Jan. 10, 2025 /PRNewswire/ -- The New York Stem Cell Foundation (NYSCF) Research Institute today announced they have...Johnson & Johnson submits application to the European Medicines Agency seeking approval of a new indication for IMBRUVICA® (ibrutinib) in adult patients with previously untreated mantle cell lymphoma (MCL) who are eligible for autologous stem cell transplant
The European MCL Network Phase 3 TRIANGLE study, evaluated ibrutinib in combination with induction immunochemotherapy, both with and without an autologous stem cell transplant, followed by 24 months fixed-duration ibrutinib therapy1DARZALEX® (daratumumab) SC-based regimens improve MRD negativity and progression-free survival in newly diagnosed multiple myeloma, and overall survival in AL amyloidosis
New analysis from Phase 3 CEPHEUS study demonstrates 85 percent of patients who achieved MRD negativity (10-6) with daratumumab SC were progression free at 4.5 years1
Top Companies in United States
Top 10 companies in United States by revenue
Top 10 companies in United States by number of employees
Top 10 companies in United States by total funding amount
Frequently Asked Questions Regarding Johnson & Johnson Innovative Medicine
At Johnson & Johnson Innovative Medicine, we are leading where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential me... Read More